Truist initiated coverage of Centessa (CNTA) with a Buy rating and $30 price target The firm sees “significant upside potential” for ORX750 in Narcolepsy and Idiopathic Hypersomnia, says the analyst, who views orexin-2 receptor agonist’s such as ORX750 as “poised to become the new standard-of-care.” While acknowledging that ORX750 is slightly behind competitors, the analyst thinks the drug has the potential to differentiate on safety, efficacy and dosing convenience.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CNTA:
- Positive Market Outlook for Centessa Pharmaceuticals Driven by Promising Developments in Orexin Agonist Class
- Optimistic Buy Rating for Centessa Pharmaceuticals Driven by Orexin Agonist Market Potential and Positive Safety Profile
- Centessa Pharmaceuticals Positioned for Leadership in Orexin Agonist Market with Promising ORX750 Candidate
- Centessa Pharmaceuticals Approves Key Resolutions at AGM
- Centessa Pharmaceuticals Gains FDA Clearance for ORX142 Study